[1]
|
E. Van Ermengem, “A New Anaerobic Bacillus and Its Relation to Botulism,” Clinical Infectious Diseases, Vol. 1, No. 4, 1979, pp. 701-709. doi:10.1093/clinids/1.4.701
|
[2]
|
C. L. Comella, M. Brin and J. Jankovic, “Biochemistry of Botulinum Toksin Type B,” Neurology, Vol. 55, No. 12, 2000, pp. 22-28.
|
[3]
|
A. S. V. Burgen, F. Dickens and L. J. Zatman, “The Action of Botulinum Toxin on the Neuromuscular Junction,” Journal of Physiology, Vol. 109, No. 1-2, 1949, pp. 10-24.
|
[4]
|
A. B. Scott, “Botulinum Toxin Injection into Extraocular Muscles as an Alternative to Strabismus Surgery,” Journal of Pediatic Ophtalmology and Strabismus, Vol. 17, No. 10, 1980, pp. 1044-1049.
|
[5]
|
D. D. Dykstra, A. A. Sidi, A. B. Scott, et al., “Effects of Botulinum A Toxin on Detrusorsphincter Dyssynergia in Spinal Cord Injury Patients,” The Journal of Urology, Vol. 139, No. 2, 1988, pp. 919-922.
|
[6]
|
H. C. Kuo, “Botulinum A Toxin Urethral Injection for the Treatment of Lower Urinary Tract Dysfunction,” The Journal of Urology, Vol. 170, No. 5, 2003, pp. 1908-1912.
doi:10.1097/01.ju.0000091281.50081.f0
|
[7]
|
B. Schurch, M. Stohrer, G. Kramer, et al., “Botulinum-A Toxin for Treating Detrusor Hyperreflexia in Spinal Cord Injured Patients: A New Alternative to Anticholinergic Drugs Preliminary Results,” The Journal of Urology, Vol. 164, No. 3, 2000, pp. 692-697.
doi:10.1016/S0022-5347(05)67283-7
|
[8]
|
M. Chancellor, M. O’Leary, J. Erickson, et al., “Successful Use of Bladder Botulinum Toxin Injection to Treat Refractory Overactive Bladder,” The Journal of Urology, Vol. 169, Suppl. 4, 2003, p. 351.
|
[9]
|
D. Zermann, M. Ishigooka, J. Schubert, et al., “Perisphincteric Injection of Botulinum Toxin Type A: A Treatment Option for Patients with Chronic Prostatic Pain?” European Urology, Vol. 38, No. 4, 2000, pp. 393-399.
doi:10.1159/000020314
|
[10]
|
S. K. Jarvis, J. A. Abbott, M. B. Lenart, et al., “Pilot Study of Botulinum Toxin Type A in the Treatment of Chronic Pelvic Pain Associated with Spasm of the Levator Ani Muscles,” Australian and New Zealand Journal of Obstetics and Gynaecology, Vol. 44, No. 1, 2004, pp. 46-50. doi:10.1111/j.1479-828X.2004.00163.x
|
[11]
|
M. Khera, T. B. Boone and C. P. Smith., “Botulinum Toxin Type A: A Novel Approach to the Treatment of Recurrent Urethral Strictures,” The Journal of Urology, Vol. 172, No. 2, 2004, pp. 574-575.
doi:10.1097/01.ju.0000130652.27541.22
|
[12]
|
P. Abrams, L. Cardozo, M. Fall, et al., “The Standardization of Terminology of Lower Urinary Tract Function: Report from the Standardisation Sub-Committee of the International Continence Society,” Neurourology and Urodynamics, Vol. 21, No. 2, 2002, pp. 167-178.
doi:10.1002/nau.10052
|
[13]
|
T. M. Kessler, H. Danuser, M. Schumacher, et al., “Botulinum A Toxin Injections into the Detrusor: An Effective Treatment in Idiopathic and Neurogenic Detrusor Overactivity?” Neurourology and Urodynamics, Vol. 24, No. 3, 2005, pp. 231-236. doi:10.1002/nau.20105
|
[14]
|
R. Popat, A. Apostolidis, V. Kalsi, et al., “Comparison between the Response of Patients with Idiopathic Detrusor Overactivity and Neurogenic Detrusor Overactivity to the First Intradetrusor Injection of Botulinum-A Toxin,” The Journal of Urology, Vol. 174, No. 2, 2005; pp. 984-989.
doi:10.1097/01.ju.0000169480.43557.31
|
[15]
|
M. Harper, R. B. Popat, R. Dasgupta, et al., “Minimally Invasive Technique for Outpatient Local Anaesthetic Administration of Intradetrusor Botulinum Toxin in Intractable Detrusor Overactivity,” BJU International, Vol. 92, No. 3, 2003; pp. 325-326.
doi:10.1046/j.1464-410X.2003.04312.x
|
[16]
|
D. E. Rapp, A. Lucioni, E. E. Katz, et al., “Use of Botulinum-A Toxin for the Treatment of Refractory Overactive Bladder Symptoms: An Initial Experience,” Urology, Vol. 63, No. 3, 2004, pp. 1071-1075.
doi:10.1016/j.urology.2004.01.041
|
[17]
|
C. P. Smith and M. B. Chancellor, “The Emerging Role of Botulinum Toxin in the Management of Voiding Dysfunction,” The Journal of Urology, Vol. 171, No. 6, 2004, pp. 2128-2137. doi:10.1097/01.ju.0000127725.48479.89
|
[18]
|
C. P. Smith, S. Nishuguchi, M. O’Leary, et al., “Single Institution Experience in 110 Patients with Botilinum A Toxin Injection into Bladder or Urethra,” Urology, Vol. 65, No. 1, 2005, pp. 37-41.
doi:10.1016/j.urology.2004.08.016
|
[19]
|
H. Schulte-Baukloh, T. Michael, B. Sturzebecher, et al., “Botulinum-A Toxin Detrusor Injection as a Novel Approach in the Treatment of Bladder Spasticity in Children with Neurogenic Bladder,” European Urology, Vol. 44, No. 1, 2003, pp. 139-143.
doi:10.1016/S0302-2838(03)00136-2
|
[20]
|
A. Reitz, M. Stohrer, G. Kramer, et al., “European Experience of 200 Cases Treated with Botulinum-A Toxin Injections into the Detrusor Muscle for Urinary Incontinence Due to Neurogenic Detrusor Overactivity,” European Urology, Vol. 45, No. 4, 2004, pp. 510-515.
doi:10.1016/j.eururo.2003.12.004
|
[21]
|
T. L. Frenkl and R. R. Rackley, “Injectable Neuromodulatory Agents: Botulinum Toxin Therapy,” Urologic Clinics of North America, Vol. 32, No. 1, 2005, pp. 89-99.
doi:10.1016/j.ucl.2004.09.005
|
[22]
|
C. P. Smith, S. Nishuguchi, M. O’Leary, et al., “Single Institution Experience in 110 Patients with Botilinum A Toxin Injection into Bladder or Urethra,” Urology, Vol. 65, No. 1, 2005, pp. 37-41.
doi:10.1016/j.urology.2004.08.016
|
[23]
|
I. F. Ghalayini and M. A. Al-Ghazo, “Intradetrusor Injection of Botulinum-A Toxin in Patients with Idiopathic and Neurogenic Detrusor Overactivity: Urodynamic Outcome and Patient Satisfaction,” Neurourology and Urodynamics, Vol. 26, No. 4, 2007, pp. 531-536.
doi:10.1002/nau.20403
|